H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Veru (VERU) today and set a price target of $21.00. The company’s shares closed last Tuesday at $15.22.
According to TipRanks.com, Chen is a top 25 analyst with an average return of 84.6% and a 64.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru with a $24.75 average price target, implying a 59.7% upside from current levels. In a report issued on February 10, Oppenheimer also assigned a Buy rating to the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
Based on Veru’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $14.62 million and net profit of $17.23 million. In comparison, last year the company earned revenue of $10.58 million and had a GAAP net loss of $3.31 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company’s urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
